Physician-Led Webinar Sponsored by Perimeter Medical Imaging AI Highlights Advancements in Intraoperative Specimen Imaging
Prestigious panel of physician experts provide commentary on Perimeter’s potentially transformative and disruptive “OCT” technology
TORONTO, Ontario--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced that a physician-led webinar – organized by Perimeter as an industry event through the American Society of Breast Surgeons (ASBrS) – is now available for replay on Perimeter’s website.
Perimeter recently announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Optical Coherence Tomography (OCT) Imaging System (v2.1), which is designed to examine tissue microstructures during surgical procedures by providing cross-sectional, real-time margin visualization. Perimeter’s technology was developed in close collaboration with expert physicians and clinicians to ensure a streamlined integration into current surgical workflows and address a pressing need for “real-time” images to aid in margin visualization. Perimeter is now actively ramping up its commercialization efforts to bring its OCT Imaging System to the U.S. market.
The ASBrS webinar entitled “Next Generation in Surgical Specimen Imaging with Future AI Enhancements” features expert breast cancer surgeons who explore how Optical Coherence Tomography (OCT), a high-resolution imaging modality commonly used in ophthalmology and cardiology, is ideally suited to visualizing margins during a surgical procedure. In addition, the physician panelists offer insights into the potential future use of Artificial Intelligence (AI) in the operating room and for specimen imaging.
The prestigious panel of physicians was made up of key opinion leaders including:
- Hank Schmidt, MD, PhD, Associate Professor of Surgery, Mount Sinai School of Medicine, Dubin Breast Center, Tish Cancer Institute, New York, NY
- Beth DuPree, MD, FACS, ABOIM, Medical Director, Oncology Service Line Centers of Northern Arizona, Northern Arizona Healthcare, Sedona, AZ
- Alastair Thompson, BSc (Hons), MBChB, MD, FRCS (Ed), Professor and Chief, Section of Breast Surgery, Division of Surgical Oncology, Baylor College of Medicine, Houston, TX
Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “With our recent 510(k) clearance, we are focusing our efforts on bringing our novel OCT Imaging System to physicians in the U.S. We are grateful to all of the esteemed panelists who shared with other ASBrS members their views on new developments in specimen imaging and the potential to reduce re-excision rates, improve patient outcomes, and lower healthcare costs with Perimeter’s transformative and disruptive technology. I encourage those who want to learn more to access the on-demand replay of this presentation. In parallel with our ongoing commercialization efforts, we continue to develop our proprietary AI technology through clinical development under our ATLAS AI project to support next-gen advancements in our technology platform.”
About Perimeter Medical Imaging AI, Inc.
Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF)(FSE:4PC) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. Perimeter’s OCT Imaging platform is a point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard of care tissue assessment for decision making during the procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter’s OCT Imaging platform is cleared by the FDA as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. In addition, Perimeter is developing advanced artificial intelligence/machine learning image assessment tools intended to increase the efficiency of review through its ATLAS AI project, which was made possible, in part, by a US$7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT), a leading state body that funds cancer research.
Perimeter’s ticker symbol “PINK” is a reference to the pink ribbons used during Breast Cancer Awareness Month by the Canadian Cancer Society and the American Cancer Society, driving home the company’s dedication to helping surgeons, radiologists and pathologists use Perimeter’s imaging technology in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results, and may include statements or information regarding the timing of and results from clinical studies, the commercialization of Perimeter’s OCT Imaging System, future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, financial results, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding potential future development and commercialization activities and the terms of options to be issued are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described the joint information circular dated May 12, 2020, prepared in respect of the securityholder meetings held on June 17, 2020 a copy of which is available on Perimeter’s SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. In particular, we note the risk that our technology may not achieve the anticipated benefits in terms of surgical outcomes. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
Corporate Communications / Investor Relations
Perimeter Medical Imaging AI, Inc.
Source: Perimeter Medical Imaging AI, Inc.
Released April 6, 2021